Exenatide Meets Key Endpoints in IIH Clinical Trial
Filed with ASX · · 8 pages · English and French
Invex Therapeutics Ltd. on 6ix
In the deck
Earlier from Invex Therapeutics
- Appendix 4D and Half-year Report
- Phase II Recruitment Completed
- Japanese Patent Granted
- Preliminary Final Report
Later from Invex Therapeutics
- Succesful $26 million Share Placement
- Phase II Clinical Results and Capital Raising Presentation
- Notice of Allowance for Key US Exenatide Patent
- Initial FDA and EMA Advice on Presendin Development
- Quarterly Report and Appendix 4C
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics